Corkeron M, Pereira P, Makrocanis C
Intensive Care Unit, The Townsville Hospital, Queensland.
Anaesth Intensive Care. 2004 Oct;32(5):666-9. doi: 10.1177/0310057X0403200510.
The administration of magnesium sulphate is a proposed novel therapy for Irukandji syndrome'. In this non-randomized, unblinded case series, data from ten patients who received magnesium salts are reviewed. Magnesium sulphate boluses of 10 to 20 mmol, in the six patients for which there was adequate data, reduced pain scores immediately after administration from 8.7+/-1.5 to 2.8+/-2.8 (Wilcoxon rank-sum test, P=0.03). In ten patients blood pressure decreased with a mean difference of -18 mmHg in mean arterial pressure. Magnesium requirements in individual patients varied markedly. Pain on injection occurred in four patients, three of whom had received peripherally administered magnesium chloride, and one patient reported transient ptosis after administration of magnesium sulphate 166 mmol over 18 hours in the setting of severe Irukandji syndrome. Magnesium sulphate administration appears to attenuate pain and hypertension in Irukandji syndrome and warrants further evaluation in this setting.
硫酸镁给药是一种针对伊鲁坎吉综合征提出的新型疗法。在这个非随机、非盲法的病例系列中，回顾了10例接受镁盐治疗患者的数据。在有足够数据的6例患者中，10至20 mmol的硫酸镁推注使给药后疼痛评分立即从8.7±1.5降至2.8±2.8（威尔科克森秩和检验，P = 0.03）。10例患者血压下降，平均动脉压平均差值为-18 mmHg。个体患者对镁的需求量差异显著。4例患者出现注射疼痛，其中3例接受外周注射氯化镁，1例患者在严重伊鲁坎吉综合征情况下18小时内静脉滴注166 mmol硫酸镁后报告有短暂上睑下垂。硫酸镁给药似乎可减轻伊鲁坎吉综合征的疼痛和高血压，在此情况下值得进一步评估。
